Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Fagron NV | EU:FAGR | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.54 | 2.90% | 19.18 | 19.10 | 19.20 | 19.18 | 18.70 | 18.70 | 44,914 | 16:36:19 |
From Feb 2025 to Mar 2025
Regulated information – inside information
Nazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2025 – 7AM CET
Fagron publishes its annual report 2024
Fagron, the leading global player in pharmaceutical compounding, today publishes its annual report 2024. Discussion of the annual report and the approval of the financial statements will be put on the agenda of the annual general meeting of shareholders scheduled for 12 May 2025.
The annual report is available in the official Dutch version and in English translation on Fagron’s website.
Further information
Ignacio Artola
Global Investor Relations Leader
Tel. +34 670 385 795
ignacio.artola@fagron.com
About Fagron
Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 30 countries around the world.
The Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.
In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.
Attachment
1 Year Fagron NV Chart |
1 Month Fagron NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
